Jun. 10 at 11:24 AM
$NUVL: Nuvalent stock is beginning to experience strong uplift due to their agreement to be acquired by GSK, valuing it at
$124 per share. It's most recent volume was at 51.6 million shares compared to average 1.48 million shares for the past three months. GSK wants to acquire it due to their immense success in clinical trials. Analysts believe their drug therapies can reach peak annual sales of
$4 billion when they are currently valued at 9.74 billion. The stock is well-poised to run up some more.
$PDC: Perpetuals Ltd stock, which specializes in blockchain-based products and solutions has shown strong recent bullish momentum. Total revenue has also grown dramatically by 146% YoY recently. The 10-day EMA stands very close to the recent closing price, which means the stock is almost ready to run. The RSI still remains neutral even amidst growing volume and bullish interest.
